Genomed SA
WSE:GEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genomed SA
Total Liabilities & Equity
Genomed SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genomed SA
WSE:GEN
|
Total Liabilities & Equity
zł12.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
M
|
Mabion SA
WSE:MAB
|
Total Liabilities & Equity
zł120.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Total Liabilities & Equity
zł15.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
B
|
Bioton SA
WSE:BIO
|
Total Liabilities & Equity
zł764.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
U
|
Urteste SA
WSE:URT
|
Total Liabilities & Equity
zł29.6m
|
CAGR 3-Years
41%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Total Liabilities & Equity
zł304.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
30%
|
CAGR 10-Years
7%
|
|
Genomed SA
Glance View
Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
See Also
What is Genomed SA's Total Liabilities & Equity?
Total Liabilities & Equity
12.4m
PLN
Based on the financial report for Dec 31, 2025, Genomed SA's Total Liabilities & Equity amounts to 12.4m PLN.
What is Genomed SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
7%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Genomed SA have been 6% over the past three years , 4% over the past five years , and 7% over the past ten years .
